Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GALT's Cash-to-Debt is ranked higher than
100% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:GALT's Interest Coverage is ranked higher than
99% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GALT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -24.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -243.59
NAS:GALT's ROE % is ranked lower than
97% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:GALT: -243.59 )
Ranked among companies with meaningful ROE % only.
NAS:GALT' s ROE % Range Over the Past 10 Years
Min: -1658.88  Med: -153.68 Max: -107.68
Current: -243.59
-1658.88
-107.68
ROA % -126.30
NAS:GALT's ROA % is ranked lower than
97% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:GALT: -126.30 )
Ranked among companies with meaningful ROA % only.
NAS:GALT' s ROA % Range Over the Past 10 Years
Min: -1309.12  Med: -143.39 Max: -71.42
Current: -126.3
-1309.12
-71.42
3-Year EBITDA Growth Rate 0.80
NAS:GALT's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:GALT: 0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.6 Max: 11.4
Current: 0.8
0
11.4
3-Year EPS without NRI Growth Rate -16.40
NAS:GALT's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:GALT: -16.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GALT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -5 Max: 36.2
Current: -16.4
-33.7
36.2
GuruFocus has detected 2 Warning Signs with Galectin Therapeutics Inc $NAS:GALT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GALT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

Q1 2017

GALT Guru Trades in Q1 2017

Charles Brandes 28,500 sh (New)
» More
Q2 2017

GALT Guru Trades in Q2 2017

Charles Brandes 28,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2017-03-31 New Buy$0.95 - $2.33 $ 1.9126%28,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:COSM, NAS:ATXI, NAS:SCYX, OTCPK:MCOA, NAS:EVOK, NAS:FCSC, NAS:JNP, NAS:PSDV, OTCPK:SENZ, NAS:BPTH, OTCPK:ELTP, NAS:LPCN, XCNQ:IAN, NAS:OREX, OTCPK:STNY, NAS:IMMY, NAS:PTX, NAS:VERU, NAS:SNOA, NAS:APRI » details
Traded in other countries:PHPN.Germany,
Headquarter Location:USA
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Top Ranked Articles about Galectin Therapeutics Inc

Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
Autoimmune Disease Patent Granted to Galectin Therapeutics
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease

Ratios

vs
industry
vs
history
EV-to-EBIT -3.50
GALT's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. GALT: -3.50 )
Ranked among companies with meaningful EV-to-EBIT only.
GALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.77  Med: 0 Max: 0
Current: -3.5
-4.77
0
EV-to-EBITDA -3.50
GALT's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. GALT: -3.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
GALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.77  Med: 0 Max: 0
Current: -3.5
-4.77
0
Current Ratio 2.66
GALT's Current Ratio is ranked higher than
61% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. GALT: 2.66 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.94 Max: 23.21
Current: 2.66
0.2
23.21
Quick Ratio 2.66
GALT's Quick Ratio is ranked higher than
70% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. GALT: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.94 Max: 23.21
Current: 2.66
0.2
23.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.50
GALT's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. GALT: -20.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -19.9 Max: -10.6
Current: -20.5
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.36
GALT's Price-to-Net-Cash is ranked higher than
51% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. GALT: 17.36 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GALT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 12.17 Max: 210
Current: 17.36
2.69
210
Earnings Yield (Greenblatt) % -28.56
GALT's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. GALT: -28.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -28.56
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.60
Beta3.11
Short Percentage of Float3.31%
52-Week Range $0.49 - 3.68
Shares Outstanding (Mil)35.05

Analyst Estimate

Dec17 Dec19 Dec20
Revenue (Mil $)
EPS ($) -0.40 -0.87 -0.94
EPS without NRI ($) -0.40 -0.87 -0.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:GALT

Headlines

Articles On GuruFocus.com
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Sep 12 2017 
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017 
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Busi Aug 18 2017 
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update Aug 14 2017 
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics Jul 25 2017 
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics Jun 21 2017 
Autoimmune Disease Patent Granted to Galectin Therapeutics Jun 06 2017 
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update May 15 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health a May 03 2017 

More From Other Websites
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of... Sep 12 2017
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017
Earnings Review and Free Research Report: Zoetis’ Results Beat Estimates in EPS and Revenues;... Aug 28 2017
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides... Aug 18 2017
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update Aug 14 2017
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics Jul 25 2017
Galectin Therapeutics to Present at the Singular Research Summer Conference Jul 07 2017
Ammo, Inc. Appoints Two Senior Executives to Board of Directors Jun 29 2017
Can The Uptrend Continue for Galectin Therapeutics (GALT)? Apr 28 2017
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Apr 24 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Apr 20 2017
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? Apr 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}